BofA analyst Jason Gerberry downgraded Cara Therapeutics to Underperform from Neutral with a price target of $6, down from $13. The launch of IV Korsuva is underwhelming, the analyst tells investors in a research note. The firm now forecasts lower sales during the early launch and views the stock’s risk/reward as skewed to the downside.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on CARA:
- Cara Therapeutics price target lowered to $22 from $26 at Needham
- Cara Therapeutics price target lowered to $25 from $29 at Canaccord
- Cara Therapeutics price target lowered to $20 from $25 at H.C. Wainwright
- Cara Therapeutics price target lowered to $13 from $25 at Piper Sandler
- CARA Plunges after a Miss on the Topline and Bottomline
